Deanfields findings led to media coverage on the potential wider benefits of semaglutide, including a front-page story in The Times in which he claimed: a large number of potential patients who have cardiovascular disease would benefit from use of this drug
We already know that Tirzepatide reduces key markers of inflammation
Mu Y, Bao X, Eliaschewitz FG, et al
An insurance plan may evaluate them under different medical and pharmacy benefits
The injectable version allows for a higher, more consistent dose of semaglutide over the course of the treatment, leading to greater reductions in body weight
Furthermore, research into this area is ongoing, and more studies are needed to fully understand the relationship between cannabis use and anhedonia